1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1002/(SICI)1097-0142(19970401)79:7%3C1428::AID-CNCR21%3E3.0.CO" target="_blank" rel="noreferrer">http://doi.org/10.1002/(SICI)1097-0142(19970401)79:7%3C1428::AID-CNCR21%3E3.0.CO</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain
Publisher
An entity responsible for making the resource available
Cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
1997
Subject
The topic of the resource
Female; Humans; Analgesics; Middle Aged; Double-Blind Method; Cross-Over Studies; Comparative Study; Neoplasms/complications; Delayed-Action Preparations; Drug Evaluation; Hydromorphone/administration & Male; Opioid/administration & dosage; Oxycodone/administration & Pain/drug therapy
Creator
An entity primarily responsible for making the resource
Hagen NA; Babul N
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/(SICI)1097-0142(19970401)79:7%3C1428::AID-CNCR21%3E3.0.CO" target="_blank" rel="noreferrer">10.1002/(SICI)1097-0142(19970401)79:7%3C1428::AID-CNCR21%3E3.0.CO</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
Description
An account of the resource
BACKGROUND: The use of oxycodone to treat chronic cancer pain has been hampered by its short elimination half-life, which necessitates administration every 4 hours. This study compared the clinical efficacy and safety of a novel oxycodone formulation with that of hydromorphone in the treatment of cancer pain. METHODS: In a double-blind crossover study, 44 patients with stable cancer pain were randomized to controlled-release oxycodone or controlled-release hydromorphone, each given every 12 hours for 7 days. Pain intensity, nausea, and sedation were assessed by patients four times daily, and breakthrough analgesia was recorded. RESULTS: Thirty-one patients completed the study (18 women, 13 men; mean age, 56 +/- 3 years) and received a final controlled-release oxycodone dose of 124 +/- 22 mg per day and a final controlled-release hydromorphone dose of 30 +/- 6 mg per day. There were no significant differences between treatments in overall Visual Analogue Scale (VAS) pain intensity (VAS 28 +/- 4 mm vs. 31 +/- 4 mm), categorical pain intensity (1.4 +/- 0.1 vs. 1.5 +/- 0.1), daily rescue analgesic consumption (1.4 +/- 0.3 vs. 1.6 +/- 0.3), sedation scores (24 +/- 4 mm vs. 18 +/- 3 mm), nausea scores (15 +/- 3 mm vs. 13 +/- 3 mm), or patient preference. Two patients experienced hallucinations on controlled-release hydromorphone, but none did while receiving controlled-release oxycodone. CONCLUSIONS: Controlled-release oxycodone demonstrated excellent pharmacodynamic characteristics, analgesic efficacy, and safety as compared with controlled-release hydromorphone and represents an important new therapeutic option for cancer pain management.
1997
Analgesics
Babul N
Backlog
Cancer
Comparative Study
Cross-Over Studies
Delayed-Action Preparations
Double-Blind Method
Drug Evaluation
Female
Hagen NA
Humans
Hydromorphone/administration & Male
Journal Article
Middle Aged
Neoplasms/complications
Opioid/administration & dosage
Oxycodone/administration & Pain/drug therapy